A Phase II study has shown that trastuzumab-DM1 (T-DM1) shrank tumours in one-third of women who had already taken seven medicines on average for advanced HER2-positive breast cancer.
The primary endpoint of the trial, which evaluated single-agent T-DM1 in 110 women, was a complete or partial tumour shrinkage of at least 30%, seen in two tumour assessments at least 28 days apart.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
T-DM1 is an antibody-drug conjugate, which attaches trastuzumab and DM1 together using a stable linker that is capable of destroying cancer cells.
Low levels of platelets in the blood (7%), fatigue (5%) and cellulitis (4%) were the most common severe adverse events of using T-DM1, the study observed.
Swiss drugmaker Roche has licensed the technology for T-DM1 under an agreement with ImmunoGen and submitted a Biologics License Application for the drug to the US Food and Drug Administration.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
